ScripIndividual Chinese biotech financings backed by venture capital and private equity firms have been hovering below the $50m mark over the past few months. However, a handful of drug hunters focused on
ScripChinese biotechs continued to secure smaller-sized fundings backed by venture capital and private equity firms in September and October, with the single largest fundraising standing at $42m. Shanghai-